IRIS - Res&Arch Institutional Research Information System - Research & Archive

BOLLI, Geremia Brunetto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.490
EU - Europa 6.017
AS - Asia 4.833
SA - Sud America 882
Continente sconosciuto - Info sul continente non disponibili 437
AF - Africa 134
OC - Oceania 22
Totale 20.815
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.124
SG - Singapore 2.324
UA - Ucraina 1.094
IE - Irlanda 836
RU - Federazione Russa 835
IT - Italia 760
SE - Svezia 751
CN - Cina 685
BR - Brasile 668
HK - Hong Kong 520
FR - Francia 445
DE - Germania 411
VN - Vietnam 408
FI - Finlandia 321
GB - Regno Unito 209
TR - Turchia 164
CA - Canada 145
BD - Bangladesh 144
KR - Corea 138
IN - India 98
AR - Argentina 70
ES - Italia 70
MX - Messico 56
AT - Austria 55
PL - Polonia 53
ZA - Sudafrica 50
JP - Giappone 43
CO - Colombia 41
IQ - Iraq 41
NL - Olanda 35
PK - Pakistan 33
UZ - Uzbekistan 33
CH - Svizzera 30
GT - Guatemala 30
ID - Indonesia 30
CR - Costa Rica 28
PH - Filippine 27
SA - Arabia Saudita 27
EC - Ecuador 25
TT - Trinidad e Tobago 24
CZ - Repubblica Ceca 23
MA - Marocco 22
AU - Australia 20
PE - Perù 19
PR - Porto Rico 18
HN - Honduras 17
VE - Venezuela 17
BE - Belgio 16
CW - ???statistics.table.value.countryCode.CW??? 16
JM - Giamaica 14
KE - Kenya 14
MY - Malesia 14
PY - Paraguay 14
AZ - Azerbaigian 13
CL - Cile 12
GR - Grecia 11
LB - Libano 11
JO - Giordania 10
LT - Lituania 10
NI - Nicaragua 10
AE - Emirati Arabi Uniti 9
IL - Israele 9
TN - Tunisia 9
DZ - Algeria 8
EG - Egitto 8
NP - Nepal 8
RO - Romania 8
SV - El Salvador 8
BO - Bolivia 7
EE - Estonia 7
OM - Oman 7
PS - Palestinian Territory 6
RS - Serbia 6
TH - Thailandia 6
UY - Uruguay 6
AL - Albania 5
BB - Barbados 5
EU - Europa 5
DK - Danimarca 4
ET - Etiopia 4
HU - Ungheria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
GE - Georgia 3
PA - Panama 3
SC - Seychelles 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
BW - Botswana 2
CI - Costa d'Avorio 2
GF - Guiana Francese 2
GP - Guadalupe 2
KW - Kuwait 2
NZ - Nuova Zelanda 2
Totale 20.370
Salva come PNG Salva come JPEG
Città #
Singapore 1.557
Dublin 838
Chandler 772
San Jose 763
Jacksonville 583
Ashburn 576
San Mateo 538
Hong Kong 518
Santa Clara 346
Boardman 333
Council Bluffs 288
Moscow 252
Princeton 251
Medford 249
Lauterbourg 214
Altamura 206
Dong Ket 192
Wilmington 185
Lawrence 146
Beijing 137
Seoul 137
New York 127
Los Angeles 124
Andover 120
Perugia 113
Izmir 112
Munich 107
Des Moines 105
Ann Arbor 104
Ho Chi Minh City 78
Saint Petersburg 78
Helsinki 74
The Dalles 63
Piscataway 58
São Paulo 57
Rome 55
Valencia 49
Brooklyn 45
Chicago 43
Norwalk 43
Hanoi 42
Frankfurt am Main 41
Dallas 40
North Bergen 40
Milan 37
Shanghai 37
Tokyo 36
Woodbridge 36
Montreal 33
Turku 29
Warsaw 29
Atlanta 26
Orem 25
Falls Church 24
Fremont 24
Nuremberg 24
Phoenix 23
Toronto 23
Belo Horizonte 22
Tashkent 22
Denver 21
Bologna 20
San Francisco 20
Stockholm 19
Vienna 19
Amsterdam 18
Amelia 17
Buffalo 17
Guatemala City 17
Houston 16
London 16
Rio de Janeiro 16
San Paolo di Civitate 16
Brussels 15
Charlotte 15
Da Nang 15
Istanbul 15
San José 15
Baghdad 14
Changsha 14
Johannesburg 14
Willemstad 14
Ankara 13
Brasília 13
Mexico City 13
Philadelphia 13
Poplar 13
Porto Alegre 13
Falkenstein 12
Naples 12
Baku 11
Boston 11
Brno 11
Campinas 11
Manchester 11
Mumbai 11
Riyadh 11
Tianjin 11
Auburn Hills 10
Bexley 10
Totale 11.822
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 222
Adrenaline vs glucagon in the primacy of glucose counterregulation 182
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 173
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 168
Hypoglycemia 159
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 154
Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. 154
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. 153
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 145
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 144
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 143
18. Insulin required for prandial ghrelin suppression in humans 141
[Behavior of plasma androgens in cases of adrenal pathology]. 137
Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. 135
A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus. 135
Diurnal Cycling of Insulin Sensitivity in Type 2 Diabetes: Evidence for Deviation From Physiology at an Early Stage 134
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 134
Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus 133
A novel surrogate index for hepatic insulin resistance. 133
Alternative routes of insulin delivery 131
Aspetti attuali del Diabete Mellito 2002 131
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 130
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 129
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 128
Adrenergic activity and glycometabolic compensation in patients with diabetes mellitus]. 128
Contribution of amino acids and insulin to protein anabolism during meal absorption. 126
Ipoglicemia: implicazioni cliniche e impatto sulla salute 123
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 122
Adrenergic mechanisms do not contribute to glucose counterregulation during acute insulin-induced hypoglycaemia in normal man. 120
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 119
Insulin is required for prandial ghrelin suppression in humans 119
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 118
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 117
Nocturnal blood glucose control in type I diabetes mellitus. 117
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 116
Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus 116
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 115
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 114
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment. 114
[Effects of circulating anti-insulin antibodies on the kinetics of injected insulin in type I diabetes mellitus]. 112
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 111
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 110
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs 110
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 108
Establishing the deficiency of glucagon response to hypoglycemia in humans 108
Intensive insulin treatment in diabetic children 107
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 107
The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity 107
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. 107
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 107
Analysis of short-term changes in reversibly and irreversibly glycosylated haemoglobin A I: Relevance to diabetes mellitus 106
Treatment and prevention of hypoglycemia and its unawareness in Type 1 diabetes mellitus 105
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 105
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 105
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 105
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 104
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 103
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 103
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 102
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 102
Insulin treatment and its complications 100
Glucagon: the effects of its excess and deficiency on insulin action 100
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 100
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 98
Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. 98
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial 97
Hyperglycemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients 97
Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia 96
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 96
HYPERGLYCEMIA-INDUCED PLATELET ACTIVATION IN TYPE 2 DIABETES MELLITUS IS RESISTANT TO ASPIRIN BUT NOT TO A NITRIC OXIDE-DONATING AGENT. 96
Impiego dell’analogo dell’insulina glargine in una paziente affetta da diabete di tipo 2 con grave resistenza insulinica. 95
A case of neoplastic hemorrhagic pericarditis. 95
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 95
Il nuovo analogo dell’insulina ad azione ritardata glargine: caratteristiche ed uso terapeutico nel diabete mellito 94
Rational use of insulin analogues in the treatment of Type 1 diabetes mellitus 94
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 94
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 94
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). 94
Chloroquine reduces whole body proteolysis in humans 93
ROLE OF PANCREATIC BETA-CELL FUNCTION ON A-CELL RESPONSE TO HYPOGLYCEMIA IN MAN 93
Erythrocyte concentration of glycolytic phosphorylated intermediates and adenosine nucleotides in subjects with diabetes mellitus. 93
La resistenza insulinica nel diabete mellito di tipo I Effetti della terapia insulinica intensiva 92
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 92
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 91
Opinioni a confronto: quando e come usare il microinfusore rispetto alla terapia insulinica multi-iniettiva nella terapia intensiva del diabete mellito tipo 1. 90
Clinical strategies for controlling peaks and valleys: type 1 diabetes 89
Glucose variability and complications. 89
Insulins today and beyond 89
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 89
Obesity and carotid artery remodeling 89
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 88
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 88
Insulin treatment in type 1 diabetes. 87
COMPARISON OF VILDAGLIPTIN AND PIOGLITAZONE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN. 87
Glucose variability and complications. 87
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 87
Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. 84
Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus 84
Kinetic behaviour of the glucose-hemoglobin labile adduct in normal and diabetic erythrocytes. 84
Reversibility of unawareness of hypoglycemia in patients with insulinomas. 83
Totale 11.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.629
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.629
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.293 0 0 0 0 52 16 10 642 18 52 210 293
2022/20232.836 259 486 38 201 204 346 6 117 1.064 7 85 23
2023/20241.090 72 122 50 19 15 10 208 24 101 52 216 201
2024/20252.731 19 313 58 132 424 53 59 230 690 173 322 258
2025/20266.098 460 347 344 721 784 456 1.138 311 766 476 155 140
2026/20272.175 189 183 340 1.312 151 0 0 0 0 0 0 0
Totale 20.815